An R&D hub for a liver therapeutic organoid technology platform will soon move into the Zhongshan Life Science Park on Ma'an Island, signaling accelerating industrial clustering in the organoid sector of Cuiheng New District.

▲Zhongshan Life Science Park

The project's backing company currently advances three core pipelines targeting such diseases as liver failure and hepatic cirrhosis. Its primary pipeline for bioartificial livers has entered Phase II trials, with conditional market approval anticipated upon trial completion.

Cuiheng New District has previously onboarded biotech players like Ruleset Dynamics and Cingular Biotech. The former aims to revolutionize organoid regeneration through an "organoid factory" concept, enabling medical-grade human tissues/organs to be engineered, customized and scaled like robotic components.